Newer developments in the treatment of Gram-positive infections (Q37636151)

21 August 2017

1 reference

title

Newer developments in the treatment of Gram-positive infections (English)

1 reference

21 August 2017

gram-positive bacteria

0 references

3

David P Nicolau

1 reference

21 August 2017

Pornpan Koomanachai

1

1 reference

PubMed ID

19929705

21 August 2017

Jared L Crandon

series ordinal

2

1 reference

PubMed ID

19929705

21 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

1 reference

21 August 2017

10

1 reference

21 August 2017

2829-2843

1 reference

21 August 2017

17

1 reference

Emergence and spread of community-associated methicillin-resistant Staphylococcus aureus in rural Wisconsin, 1989 to 1999

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Interactions of antimicrobial compounds with cross-linking agents of alginate dressings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

MRSA--the tip of the iceberg

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Serum Vancomycin Concentrations: Reappraisal of Their Clinical Value

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Trimethoprim-sulfamethoxazole revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Antimicrobial susceptibility patterns of respiratory pathogens--a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Antimicrobial resistance in Staphylococcus aureus in Australian teaching hospitals, 1989-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Structural insights into fusidic acid resistance and sensitivity in EF-G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Resistance to fusidic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Molecular analysis of fusidic acid resistance in Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Fusidic acid in septicaemia and endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Fusidic acid in skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Fusidic acid in the treatment of methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Fusidic acid adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Clinical Pharmacokinetics of Linezolid, a Novel Oxazolidinone Antibacterial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Pharmacoeconomics of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Emergence and management of drug-resistant enterococcal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Current and future management of infections due to methicillin-resistant staphylococci infections: the role of quinupristin/dalfopristin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Quinupristin-dalfopristin and linezolid: evidence and opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Tigecycline: what is it, and where should it be used?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Tigecycline pharmacokinetic/pharmacodynamic update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Tigecycline: a critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Moderate liver impairment has no influence on daptomycin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Update on daptomycin: the first approved lipopeptide antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Telavancin: a novel lipoglycopeptide for serious gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Telavancin: a novel lipoglycopeptide antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

In vitro activity of telavancin against resistant gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903357491

10.1517/14656560903357491

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19929705